drugset / Trial / NCT00969033

CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin

NCT00969033

Phase 2 Terminated 8 enrolled Daiichi Sankyo
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of CS-1008 in combination with irinotecan compared to irinotecan alone on Progression-Free Survival (PFS) in subjects with metastatic or advanced colorectal cancer (CRC) who have failed oxaliplatin-based first-line treatment.

Timeline

Start
2009-07
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject tigatuzumab Monoclonal antibody
Background Irinotecan Small molecule

Indications